MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the “Investor Calendar” section of the company’s website at: https://event.webcasts.com/starthere.jsp?ei ...

Core Insights - InspireMD, Inc. has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategy during a critical phase for the company [1][2] Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [5] Leadership Appointment - Dr. Soukas brings extensive experience in vascular intervention, serving as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University, where he founded the Vascular and Endovascular Medicine Fellowship Program [2][3] - His background includes being a principal investigator in over 24 carotid stenting trials and more than 150 endovascular trials, along with delivering over 300 invited lectures and publishing numerous peer-reviewed papers [3] Strategic Vision - Dr. Soukas expressed his commitment to guiding InspireMD in clinical and medical topics, aiming to enhance awareness of the CGuard Prime stent platform and improve patient care through collaboration with clinical partners [4]

Core Insights - InspireMD, Inc. will release its third quarter 2025 financial results on November 4, 2025, and will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss these results and recent highlights [1]. Company Overview - InspireMD, Inc. is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes [1]. - The company utilizes its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [2]. Investor Information - Interested parties can access the live earnings call via telephone or through a live webinar on InspireMD's website, with a replay available shortly after the call [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR [2].

Company Overview - InspireMD, Inc. is a developer of the CGuard® Prime carotid stent system aimed at preventing strokes [1] - The company is publicly traded on Nasdaq under the ticker symbol NSPR [5] Leadership Appointment - Dan Dearen has been appointed to the Board of Directors, bringing nearly 40 years of experience in the medical device and life sciences sectors [1][2] - His previous roles include President, co-Founder, and Chief Financial Officer of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024 [2][3] Strategic Importance - The appointment of Mr. Dearen is seen as timely as InspireMD continues its U.S. commercial launch of the CGuard Prime stent system [2] - The company aims to lead the carotid intervention market and execute its long-term value-creation strategy [2] Market Potential - Mr. Dearen expressed optimism about InspireMD's potential to change the standard of care in vascular medicine and improve patient outcomes [2] - The company utilizes proprietary MicroNet™ mesh technology to enhance the effectiveness of its carotid stenting products [5]

Core Viewpoint - InspireMD, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, highlighting its focus on the CGuard® Prime carotid stent system for stroke prevention [1] Company Overview - InspireMD, Inc. aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, emphasizing superior acute results and long-term stroke-free outcomes [2] - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2]

Core Viewpoint - InspireMD, Inc. has appointed Raymond W. Cohen to its Board of Directors, bringing over 40 years of experience in medical technology to enhance the company's strategic vision and operational execution [1][2]. Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [6]. Leadership Experience - Raymond W. Cohen has a notable track record, having co-founded Axonics, Inc., which went public in 2018 and was acquired by Boston Scientific for $3.7 billion in November 2024 [2]. - Cohen previously served as Chairman of SoniVie Ltd., which was acquired by Boston Scientific for $600 million, and has held leadership roles in various medical technology companies [3][4]. Strategic Goals - The company is shifting its focus towards the commercial launch of the CGuard Prime stent system following its recent PMA approval, with expectations of capturing market share and delivering long-term value [2][5]. - Cohen expressed confidence in InspireMD's potential to lead the U.S. carotid stent market due to its innovative approach and commitment to clinical excellence [5].

Core Insights - InspireMD, Inc. has raised approximately $58 million through a PIPE financing and warrant exercise, following the FDA's approval of its CGuard® Prime carotid stent system [1][2][3] - The PIPE financing generated gross proceeds of $40.1 million, with participation from existing and new investors, and the exercise of warrants contributed an additional $17.9 million [2][3] - The funds will be utilized for operations including sales and marketing, research and development, and general corporate purposes [4] Financing Details - The PIPE financing involved the issuance of 16,556,184 shares of common stock at a purchase price of $2.42 per share [2] - The transaction is expected to close by August 1, 2025, subject to customary conditions [3] - BofA Securities acted as the exclusive placement agent for the PIPE [4] Strategic Objectives - The CEO of InspireMD stated that the transaction strengthens the company's balance sheet and positions it for rapid commercial growth in the carotid intervention market [3] - The company aims to leverage its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting [7]